Trial reportPediatric pulmonology2026
Early Versus Conventional Discontinuation of Caffeine Therapy for Apnea of Prematurity: A Randomized Controlled Trial-The DECaf Trial.
Trial report in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWhile caffeine therapy is well-established for managing apnea of prematurity (AOP), standardized protocols for its discontinuation are lacking. This study evaluated whether earlier cessation at 33 weeks postmenstrual age (PMA) is as safe as conventional discontinuation at 34 weeks.
methodsPreterm neonates (26-32 weeks of gestation) on caffeine for AOP, who were off respiratory support and apnea-free for 5 consecutive days by 33 weeks PMA, were randomized to early discontinuation (Group A) or conventional discontinuation at 34 weeks PMA (Group B). The primary outcome was recurrence of apnea (RAP) post-cessation.
resultsApnea recurrence was similar between groups (13.7% vs. 10%; OR 1.44, p = 0.71). Caffeine duration was significantly shorter in Group A (21.5 vs. 28.5 days, p = 0.024). No significant differences were noted in secondary outcomes or neonatal morbidities.
conclusionsEarly discontinuation of caffeine at 33 weeks PMA in stable preterm neonates appears safe and may reduce drug exposure without increasing apnea risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.